Compare Amylx Pharmaceuticals Inc (AMLX) vs 22nd Century Group Inc (XXII) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs 22nd Century Group Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.04 (market cap $1.98B), while 22nd Century Group Inc trades at $4.23 (market cap $1.46M). The key difference: Amylx Pharmaceuticals Inc is far larger — about 1356.2× 22nd Century Group Inc's market cap. Which is the better fit depends on your goals.
| AMLX | XXII | |
|---|---|---|
Market Cap | $1.98B | $1.46M |
Sector | Health | Technology |
52-Week High | $18.70 | $1.85K |
52-Week Low | $7.64 | $3.90 |
Enterprise Value | $1.70B | -$6.77M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
XXII trades at $4.23, down 2.08% on the day, amid a bearish technical signal. The company's financials show deep losses with a net income margin of -65.76% and negative ROE of -130.19% for 2026. Recent news highlights expansion of its VLN reduced-nicotine cigarettes in California and New York, aiming to capture market share. Analyst consensus is 75% buy, but earnings misses in Q4 2025 and Q1 2026 raise execution concerns.
The outlook hinges on VLN's commercial success and FDA regulatory pathway. High cash burn necessitates ongoing financing, evident in 2026's $17M financing inflow. Risks include persistent unprofitability, competitive pressures, and reliance on tobacco harm reduction narrative. Upside depends on revenue scaling and margin improvement from new retail launches.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About 22nd Century Group Inc
22nd Century Group is a plant biotechnology company that uses genetic engineering and gene editing to control the levels of nicotine in tobacco plants. Its flagship product line, VLN®, is the first and only combustible cigarette authorized by the FDA as a Modified Risk Tobacco Product (MRTP), containing 95% less nicotine than traditional cigarettes to help adult smokers smoke less.
Read more on XXII →
